LifeMD Reschedules Third Quarter 2025 Earnings Release and Conference Call to November 17
LifeMD (Nasdaq: LFMD) rescheduled its third quarter 2025 earnings release and conference call to Monday, November 17, 2025, with the press release expected at about 4:05 p.m. ET and the call at 4:30 p.m. ET. The company expects to file a Form 12b-25 notifying the SEC of a late Form 10-Q for the period ended September 30, 2025.
LifeMD identified corrections to revenue recognition and offsetting balance sheet accounts for the twelve months ended Dec 31, 2023, twelve months ended Dec 31, 2024, and the six months ended June 30, 2025. The cumulative impact is approximately $4.6 million, or roughly 1.4% of cumulative revenue for the referenced periods. The company said the adjustments will not materially change reported revenue versus guidance and will not affect cash flow or cash position.
LifeMD (Nasdaq: LFMD) ha posticipato la pubblicazione degli utili del terzo trimestre 2025 e la conference call al lunedì 17 novembre 2025, con il comunicato stampa previsto intorno alle 4:05 p.m. ET e la chiamata alle 4:30 p.m. ET. L'azienda prevede di depositare un Form 12b-25 che informa la SEC di un Form 10-Q tardivo per il periodo chiuso il 30 settembre 2025.
LifeMD ha identificato correzioni alla recognition delle entrate e ai conti di bilancio di compensazione per i dodici mesi terminati il 31 dicembre 2023, per i dodici mesi terminati il 31 dicembre 2024 e per i sei mesi terminati il 30 giugno 2025. L'impatto cumulativo è circa 4,6 milioni di dollari, o circa 1,4% delle entrate cumulate per i periodi di riferimento. L'azienda ha dichiarato che le rettifiche non modificheranno materialmente le entrate riportate rispetto alle previsioni e non influenzeranno il flusso di cassa o la posizione di liquidità.
LifeMD (Nasdaq: LFMD) reprogramó su comunicado de resultados del tercer trimestre de 2025 y la conferencia telefónica para el lunes 17 de noviembre de 2025, con el comunicado de prensa previsto alrededor de las 4:05 p.m. hora del Este y la llamada a las 4:30 p.m. hora del Este. La empresa espera presentar un Form 12b-25 notificando a la SEC de un Form 10-Q tardío para el periodo terminado el 30 de septiembre de 2025.
LifeMD identificó correcciones en el reconocimiento de ingresos y en las cuentas de balance compensatorias para los doce meses terminados el 31 de diciembre de 2023, los doce meses terminados el 31 de diciembre de 2024 y los seis meses terminados el 30 de junio de 2025. El impacto acumulado es aproximadamente 4,6 millones de dólares, o aproximadamente 1,4% de los ingresos acumulados para los periodos referenciados. La compañía dijo que los ajustes no cambiarán materialmente los ingresos reportados frente a las Guías y no afectarán el flujo de efectivo ni la posición de caja.
LifeMD(Nasdaq: LFMD)는 2025년 3분기 실적 발표 및 컨퍼런스 콜을 2025년 11월 17일 월요일로 재일정했으며, 보도자료는 대략 동부 표준시 4:05 p.m.에, 콜은 동부 표준시 4:30 p.m.에 진행될 예정입니다. 회사는 2025년 9월 30일로 종료되는 기간에 대한 지연된 Form 10-Q를 SEC에 통지하는 Form 12b-25를 제출할 것으로 예상합니다.
LifeMD는 2023년 12월 31일 종료 12개월, 2024년 12월 31일 종료 12개월, 그리고 2025년 6월 30일 종료 6개월에 대한 매출 인식 및 대조 계정의 수정사항을 확인했습니다. 누적 영향은 약 460만 달러로, 언급된 기간의 누적 매출의 약 1.4%에 해당합니다. 회사는 이러한 조정이 보고된 매출을 가이드라인과 실질적으로 다르게 만들지 않으며 현금 흐름이나 현금 위치에 영향을 미치지 않을 것이라고 밝혔습니다.
LifeMD (Nasdaq : LFMD) a reporté la publication de ses résultats du troisième trimestre 2025 et l'appel conférence à lundi 17 novembre 2025, le communiqué de presse étant prévu vers 16h05 HE et l'appel à 16h30 HE. La société prévoit de déposer un Form 12b-25 informant la SEC d'un Form 10-Q en retard pour la période terminée le 30 septembre 2025.
LifeMD a identifié des corrections à la reconnaissance des revenus et sur les comptes de bilan compensatoires pour les douze mois terminés le 31 décembre 2023, les douze mois terminés le 31 décembre 2024 et les six mois terminés le 30 juin 2025. L'impact cumulé est d'environ 4,6 millions de dollars, soit environ 1,4% du revenu cumulé pour les périodes concernées. La société a déclaré que les ajustements ne modifieront pas matériellement les revenus déclarés par rapport aux prévisions et n'affecteront pas la trésorerie ou la position de liquidités.
LifeMD (Nasdaq: LFMD) verschob die Veröffentlichung der Ergebnisse zum dritten Quartal 2025 und die Telefonkonferenz auf Montag, den 17. November 2025, wobei die Pressemitteilung voraussichtlich gegen 16:05 Uhr ET veröffentlicht wird und der Call um 16:30 Uhr ET stattfinden soll. Das Unternehmen plant, ein Form 12b-25 einzureichen, das die SEC über eine verspätete Form 10-Q für den Zeitraum endet am 30. September 2025 informiert.
LifeMD identifizierte Korrekturen bei der Umsatzanerkennung und bei offsetting balance sheet accounts für die zwölf Monate beendet am 31. Dezember 2023, die zwölf Monate beendet am 31. Dezember 2024 und die sechs Monate beendet am 30. Juni 2025. Die kumulative Auswirkung beträgt ungefähr 4,6 Millionen USD, bzw. ca. 1,4% des kumulierten Umsatzes für die referenzierten Perioden. Das Unternehmen erklärte, dass die Anpassungen die berichteten Umsätze gegenüber den Vorgaben nicht wesentlich verändern und weder den Cashflow noch die Barschaft beeinflussen werden.
LifeMD (ناسداك: LFMD) أجدولت إصدار أرباحها للربع الثالث من 2025 ومكالمة المؤتمر إلى الاثنين 17 نوفمبر 2025، مع توقع صدور البيان الصحفي حوالي 4:05 مساءً بتوقيت شرق الولايات المتحدة وقيام المكالمة في 4:30 مساءً بتوقيت شرق الولايات المتحدة. تتوقع الشركة تقديم Form 12b-25 لإبلاغ هيئة الأوراق المالية والبورصات عن نموذج 10-Q المتأخر للفترة المنتهية في 30 سبتمبر 2025.
حددت LifeMD تصحيحات لاعتماد الإيرادات وحسابات الميزانية الموازنة لمدة اثني عشر شهراً منتهية في 31 ديسمبر 2023، واثني عشر شهراً منتهية في 31 ديسمبر 2024، وستة أشهر منتهية في 30 يونيو 2025. التأثير التراكمي يقارب 4.6 مليون دولار، أو نحو 1.4% من الإيرادات التراكمية للفترات المذكورة. قالت الشركة إن هذه التعديلات لن تغيّر بشكل جوهري الإيرادات المبلغ عنها مقارنةً بالتوجيهات ولن تؤثر على التدفق النقدي أو الموقف النقدي.
- Cumulative adjustment limited to $4.6 million
- Adjustment equals about 1.4% of cumulative revenue for the referenced periods
- Company states no impact to cash flow or cash position
- Expecting to file Form 12b-25 for a late Form 10-Q
- Revenue recognition corrections span multiple periods: Dec 31, 2023, Dec 31, 2024, June 30, 2025
- Third quarter 2025 earnings release and conference call rescheduled to November 17, 2025
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual healthcare services and pharmacy, today announced that the Company has rescheduled its third quarter 2025 earnings release and conference call to Monday, November 17, 2025. The Company expects to file a Form 12b-25, as needed, notifying the U.S. Securities and Exchange Commission of a late filing of its Form 10-Q for the period ended September 30, 2025.
The change to LifeMD’s third quarter 2025 earnings release date relates to corrections the Company identified related to the recognition of revenue with offsetting related balance sheet accounts for the twelve months ended December 31, 2023, December 31, 2024 and the six months ended June 30, 2025. The cumulative impact of these changes will be approximately
LifeMD expects to issue its third quarter 2025 earnings press release on or around 4:05 p.m. Eastern time on Monday, November 17, 2025 followed by the conference call at 4:30 p.m. Eastern time. Information for the rescheduled conference call is as follows:
Conference Call & Webcast Details
| Date: | Monday, November 17th |
| Time: | 4:30 p.m. Eastern time |
| Toll-Free Dial-In: | 800-245-3047 |
| International Dial-In: | 203-518-9765 |
| Conference ID: | LIFEMD |
| Live & Archived Webcast: | Link |
About LifeMD, Inc.
LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, mental health, and weight management. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.
Cautionary Note Regarding Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the impact of recently discovered errors that originated in prior periods and were identified by the Company in the preparation of its third quarter 2025 financial statements that the Company is evaluating, including the potential impact of these matters on internal control over financial reporting. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. The preliminary determinations above are subject to adjustment as the Company prepares its financial statements and disclosures for the three and nine months ended September 30, 2025, and such adjustments may be significant. The Company's auditors have not audited, reviewed, compiled, or applied agreed-upon procedures with respect to the preliminary determinations described above. Factors that could materially affect these forward looking statements include, but are not limited to: the completion of the review of the accounting matters identified, including the potential impact on internal control over financial reporting, as well as those factors set forth in our Form 10-K (and other forms) filed with the Securities and Exchange Commission.
Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.
Investor Contact
Marc Benathen, Chief Financial Officer
marc@lifemd.com
Media Contact
Jessica Friedeman, Chief Marketing and Product Officer
press@lifemd.com
FAQ
When will LifeMD (LFMD) release third quarter 2025 results?
Why did LifeMD (LFMD) reschedule the Q3 2025 earnings call to November 17, 2025?
How large are the revenue adjustments LifeMD (LFMD) reported?
Will the revenue adjustments affect LifeMD's (LFMD) cash position?
When and how can investors join LifeMD's (LFMD) rescheduled conference call on Nov 17, 2025?
